A Study of Poziotinib in Previously Treated Participants With Locally Advanced or Metastatic NSCLC Harboring HER2 Exon 20 Mutations
Clinical trial NCT05378763 · SUSPENDED
Trial details
- NCT number
- NCT05378763
- Sponsor
- Spectrum Pharmaceuticals, Inc
- Status
- SUSPENDED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2022-05-12
- Primary completion
- 2027-12-25
- Enrollment
- 268
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.